SCHEMBL13445263

SCHEMBL13445263

Cc1ccc(S(=O)(=O)N(C)CCN(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CA2 P00918 1/20 0.51
C5AR1 P21730 1/20 0.50
ALOX15 P16050 1/20 0.50
AGER Q15109 1/20 0.50
LMNA P02545 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
POLB P06746 2/20 0.48
HDAC4 P56524 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HTT P42858 1/20 0.48
GLA P06280 1/20 0.47
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282765 0.85 MAPT (0.53) MAPTMCOLN3CA12CA9C5AR1
SCHEMBL18986533 0.85 LMNA (0.55) MAPTMCOLN3CA12CA9CA2
SCHEMBL16884872 0.83 MAPT (0.52) MAPTMCOLN3CA12CA9C5AR1
SCHEMBL20237218 0.83 MAPT (0.52) MAPTMCOLN3CA12CA9C5AR1
SCHEMBL14464155 0.83 MAPT (0.52) MAPTMCOLN3CA12CA9C5AR1
SCHEMBL5856927 0.83 HDAC4 (0.47) CA12CA9CA2LMNAHDAC4
SCHEMBL6034965 0.83 SIGMAR1 (0.59) MAPTLMNASMN1; SMN2HDAC4HDAC6
SCHEMBL7200356 0.83 KMT2A (0.55) MAPTMCOLN3C5AR1AGERLMNA
SCHEMBL3178219 0.82 MAPT (0.55) MAPTMCOLN3CA12CA9CA2
SCHEMBL16222119 0.82 CCR5 (0.51) MAPTLMNASMN1; SMN2HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US disclosed
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US disclosed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES ADK, PNP, DCK MAPT 1833/4885MCOLN3 4137/4885CA12 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.